Ioannis Pappas is currently Professor of Pharmacology and
Toxicology in the Faculty of Veterinary Medicine of the University of Thessaly,
Greece. His research topics mainly include PTD-IVT-mRNA transfer and cancer immunotherapy;
the design and development of new anticancer agents; the study of antibiotic
resistance; neurodegenerative diseases and potent targets; and the evaluation
of the potency and safety of drugs and vaccines. Part of his work is on the proliferation,
differentiation, and apoptosis of cancer cells. He has also developed a number
of chemical compounds that inhibit the c-myc oncogene, induce Nrf-2, etc. He
has recently focused on mRNA transfer for the therapy of metabolic/genetic
disorders and on CAR immunotherapy of cancer. He has
published more than 45 original articles in
reputable international journals and 80
articles at scientific conferences. He has participated in 20 research
projects. He published
two main reviews entitled “Mechanisms involved in the induced differentiation
of leukemic cells” and “In Vitro-Transcribed mRNAs as a new generation
of therapeutics at the dawn of the 21st century: Exploitation of peptides as
carriers for their intracellular delivery”. He is a co-inventor of a
patent concerning the deliverable PTD-IVT-mRNAs (WO2021/094792 A1/ 20.05.2021). He has
long experience in tissue culture, molecular biology, biochemistry, and
chemistry techniques.
Ioannis Pappas is currently Professor of Pharmacology and
Toxicology in the Faculty of Veterinary Medicine of the University of Thessaly,
Greece. His research topics mainly include PTD-IVT-mRNA transfer and cancer immunotherapy;
the design and development of new anticancer agents; the study of antibiotic
resistance; neurodegenerative diseases and potent targets; and the evaluation
of the potency and safety of drugs and vaccines. Part of his work is on the proliferation,
differentiation, and apoptosis of cancer cells. He has also developed a number
of chemical compounds that inhibit the c-myc oncogene, induce Nrf-2, etc. He
has recently focused on mRNA transfer for the therapy of metabolic/genetic
disorders and on CAR immunotherapy of cancer. He has
published more than 45 original articles in
reputable international journals and 80
articles at scientific conferences. He has participated in 20 research
projects. He published
two main reviews entitled “Mechanisms involved in the induced differentiation
of leukemic cells” and “In Vitro-Transcribed mRNAs as a new generation
of therapeutics at the dawn of the 21st century: Exploitation of peptides as
carriers for their intracellular delivery”. He is a co-inventor of a
patent concerning the deliverable PTD-IVT-mRNAs (WO2021/094792 A1/ 20.05.2021). He has
long experience in tissue culture, molecular biology, biochemistry, and
chemistry techniques.